7th Advances in Heart Failure 2024

10 e 11 de Outubro

FACULDADE DE MEDICINA DA UNIVERSIDADE DO PORTO

ZAÇÃO

FM UP



GËI DONE EVENIS

th Advances in Heart Failure 2024

10 e 11 de Outubro

FACULDADE DE MEDICINA DA UNIVERSIDADE DO PORTO

Age

What is the pathway to a personalized and early approach?

Conceição Queirós

Serviço de Cardiologia – ULS Tâmega e Sousa

10 outubro 2024



Age is among the most potent risk factors independently associated with HF

(regardless of ejection fraction, and its outcomes)



Referencies: Goyal P, Maurer MS, Roh J. Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series. JACC Heart Fail. 2024 May;12(5):795-809.



Age is a non-modifiable factor in heart failure...

Age is something we live with, that we know and that we cannot change...

Age is a non-modifiable risk factor... the number of days of life cannot be changed...



But is this the case?

Age belongs to us and is not just a question of being old or young (the **years**), but... ... is associated with an individual, changeable story/history throughout life... associate to an aging/ageing process...





Age and Aging

INSTITUTO NACIONAL DE ESTATÍSTICA Statistics Portugal



AGE "Time interval that elapses between the date of birth (day, month and year) and 0 hours on the reference date. ... is expressed incomplete years, except in the case of children under 1 year old, in which case it must be expressed in complete months, weeks or days.



AGEING (=AGING) "At the **biological level**, ageing results from the impact of the accumulation of a wide **variety of molecular and cellular damage over time**. This leads to a gradual **decrease in physical and mental capacity, a growing risk of disease and ultimately death**.

These changes are neither linear nor consistent, and they are only loosely associated with a person's age in years. "



Age vs Aging


CHRONOLOGICAL non-modifiable



Vecteezy



modifiable /non-modifiable







Chronological age





Chronological - Age

AHA/ACC/HFSA CLINICAL PRACTICE GUIDELINE

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

- <u>Heart Failure</u> (HF) is a growing health and <u>economic burden</u> for the United States, in large part because of the <u>aging</u> population.

- Although the <u>absolute number of patients with HF has partly grown</u> as a result of the <u>increasing number of</u> <u>older adults</u>, the <u>incidence</u> of HF has <u>decreased</u>.

- Divergent trends in the incidence of HF have been observed for those with HFrEF (decreasing incidence) and HFpEF (increasing incidence).



Chronological - Age

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

- In developed countries, the <u>age adjusted incidence</u> of HF maybe falling, presumably reflecting <u>better management of CV</u> <u>disease</u>, but <u>due to ageing, the overall incidence is increasing</u>.

- The prevalence increases with age: from around 1% for those aged < 55 years to > 10% in those aged 70 years or over

- Due to population growth, ageing, and the increasing prevalence of comorbidities, the absolute number of hospital admissions for HF is expected to increase considerably in the future

- **HFpEF patients** are <u>older and more often female</u>

Referencies: Theresa A McDonagh, Marco Metra, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726,



Chronological - Age

EPICA STUDY

- the **prevalence of CHF increases with age** in both sexes and tends to be slightly higher in men up to the age of 70, then it stabilises. **In women**, it continues to increase with age and becomes greater than the prevalence for men in the 70–79 years-old age group



- HF is a **syndrome associated with aging**, with a **prevalence of <u>31% in those over 70 years old</u>; in people between 50 and 59 years old it is 4%.**

- More than 90% of people are unaware of having the disease, especially women, those over 70 and patients with the form of heart failure with preserved ejection fraction.

Referencies: Ceia, F. et al. Prevalence of chronic heart failure in Southwestern Europe: The EPICA study. Eur. J. Heart Fail. 2002, 4, 531–539.; Baptista R et al. Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design - A population-based study. Rev Port Cardiol. 2023 Dec;42(12):985-995



HF along Age

Type of diseases	Pathophisiology	Examples
Congenital heart diseases	Left to right shunt (volume overload)	Ventricular septal defects
		Complete atrioventricular canal defects
		Patent ductus arteriosus
		Aorto-pulmonary windows
	Valvular regurgitation (volume overload)	Mitral regurgitation
		Aortic regurgitation
	Outflow tract obstruction (pressure overload)	Aortic stenosis
		Tunnel type subaortic stenosis
		Supravalvular aortic stenosis
		Pulmonary stenosis
		Pulmonary vein stenosis
	Coronary insufficiency (decreased O ₂ supply to cardiomyocyte)	Coronary artery anomalies
Cardiomyopathies (inherited or acquired)	Systolic dysfunction (low cardiac output) Diastolic dysfunction (elevated pulmonary	Dilated cardiomyopathy
	capillary pressure)	- Myocarditis
		- Barth syndrome
		 Carnitine deficency
		 Familial dilated cardiomyopathy
		 Neuromuscular disorder (i.e., Becker dystroph Duchenne dystrophy)
		Hypertrophic cardiomyopathy
		- Pompe diseases
		- Noonan syndrome
		 Maternal diabetes
		 Mitochondrial diseases
		 Familial hypertrophic cardiomyopathy
		Idiopathic restrictive cardiomyopathy
Arrhythmias	Systolic dysfunction (low cardiac output)	Tachycardia induced cardiomyopathy
		 Atrio-ventricular node reentry tachycardia Atrio-ventricular reentry tachycardia Ectopic atrial tachycardia
		Congenital third degree atrio-ventricular blo
Infection	Systolic dysfunction	Sepsis induced myocardial dysfunction
High output state	Volume overload	Thyrotoxicosis Systemic arteriovenous fistula Severe anemia

Pediatric heart failure:

Although the **estimated** <u>incidence</u> of heart failure <u>is relatively low</u> at 0.9–7.4 per 100,000 children, it is a disease that **carries a** <u>high burden of morbidity and</u> <u>mortality</u>, with an in-hospital mortality rate of 7–26%.

In the modern era, <u>infants</u> account for the majority (64%) of heart failure admissions in patients ≤18 years of age.

The primary cardiac diagnosis at the time of admission is <u>congenital heart disease</u> - CHDs (69% - valvular, coronary, left to right shunts, outflow tract obstruction), followed by <u>arrhythmias</u> (12–15% - tachy or congenital 3rd degree atrio-ventricular block), <u>cardiomyopathy</u> (13–14%- inherited or acquired), and <u>myocarditis</u> (~2%).

Other causes are: <u>hight output states (like hyrotoxicosis, systemic AV fistula, severe anemia)</u>, infectious and inflammatory diseases, <u>oncologic processes</u>, <u>metabolic syndromes</u>, <u>renal</u> <u>failure</u>, and <u>malnutrition</u>

Referencies: Daniele et al. Pediatric Heart Failure: A Practical Guide to Diagnosis and Management Masarone, Pediatrics & Neonatology, Volume 58, Issue 4, 303 – 312; Masarone D, et al Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatr Neonatol. 2017 Aug;58(4):303-312; Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335.



HF along Age

<u>At birth</u> – fetal <u>cardiomyopathies</u> or <u>extracardiac conditions</u> (such as sepsis, hypoglycaemia, and hypocalcaemia)

In the <u>1st week</u> - CHDs with <u>ductus-dependent systemic circulation</u> (such as severe aortic stenosis/aortic coarctation and hypoplastic left heart syndrome), in which the closure of the ductus arteriosus causes severe reduction of end-organ perfusion, are the main cause.

In the <u>1st month</u> of life - <u>CHDs with left to right shunt</u> (such as ventricular septal defects, patent ductus arteriosus, and aorto-pulmonary windows), in which pulmonary blood flow progressively increases with the fall of pulmonary resistance.



In <u>adolescence and young adults</u> HF is rarely secondary to CHDs, but is more often related to cardiomyopathies or myocarditis

Referencies: Daniele et al. Pediatric Heart Failure: A Practical Guide to Diagnosis and Management Masarone, Pediatrics & Neonatology, Volume 58, Issue 4, 303 – 312; Masarone D, et al Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatr Neonatol. 2017 Aug;58(4):303-312; Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335.



HF along Age

Given the <u>relative rarity of heart failure in pediatrics</u>, and the heterogeneity of this population, there has been a **paucity of clinical trials** that have been performed primarily in pediatric patients. As a result, <u>clinical guidelines for the treatment of pediatric</u> <u>heart failure</u> have historically been reliant on <u>expert consensus</u>, and the <u>extrapolation of data</u> from trials performed in adults.



19 Vecteezy

Referencies: Daniele et al. Pediatric Heart Failure: A Practical Guide to Diagnosis and Management Masarone, Pediatrics & Neonatology, Volume 58, Issue 4, 303 – 312; Masarone D, et al Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatr Neonatol. 2017 Aug;58(4):303-312; Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335.



HF along Age





😗 Vecteezy

- **increase of HF incidence** in young adults (< 50 years old) ... differs from the general trend noted in older patients.
- <u>men</u> seemed to be more vulnerable to premature HF than women (<u>new heart failure presenting during pregnancy</u> PPCM)





HF along Age



- <u>myocarditis–cardiomyopathy</u> and <u>IHD</u> were major causes of HF admission, with inverse probability trends according to age group (in the young population, and especially in young men, <u>ischaemic HF</u> was the predominant form of HF, and ... data suggest that it is progressively increasing:

... it may reflect true epidemiological changes linked to **increased** <u>prevalence of cardio-metabolic risk factors</u> in young people

- the young adults hospitalized for premature HF also presented with high rates of major modifiable risk factors for ischaemic <u>HF</u>, including obesity, dyslipidaemia, smoking, hypertension, and diabetes.

The observed **proportion of <u>re-hospitalization</u>** for HF or from any cause within 2 years after the first HF event is alarming.





HF along Age

Elderly :

Vecteezy

- more than 10% in those aged 70 years or over have HF
- HFpEF patients are older

- <u>some of the comorbidities of HF are more common</u> in the elderly: arrhythmias and conduction disturbances (AF, pauses and atrioventricular block), stroke, frailty, sarcopenia, iron deficiency and anaemia, kidney dysfunction, arthritis, depression, ... They can:

... <u>limit the use of certain medications or compliance</u> with non-pharmacological measures

... promote the adoption of incorrect actions (eg. self-administeredNSAIDs)

Referencies: Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895e1032; Theresa A McDonagh, Marco Metra, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure are port of the American College of Safety (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726,



HF along Age



- elderly tends to have a greater burden of illness and longer survival time with the syndrome and/or diseases "causing HF" (coronary disease, genetic or acquired cardiomyopathies such as <u>Amyloidosis</u>, DMC after cancer therapy, valvular disease (<u>aortic stenosis</u>, ...), ...

- have more frequently limitations in accessing pharmacological and non-pharmacological therapy:

... lower purchasing power, and more polypharmacy,

... eg. exercise less frequently given the greater likelihood of physical limitations



Referencies: Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895e1032; Theresa A McDonagh, Marco Metra, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure) of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726,



HF along Age

Elderly :

... due to his condition, less access to advanced HF therapies...

Secondary prevention

An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.^{162–164}

Primary prevention

An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II–III) of an ischaemic aetiology (unless they have had a MI in the prior 40 days—see below), and an LVEF \leq 35% despite \geq 3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.^{161,165} An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II–III) of a non-ischaemic aetiology, and an LVEF \leq 35% despite \geq 3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.^{161,166,167}

Table 19. Indications and Contraindications to Durable Mechanical Support³⁷

Contraindications: Absolute Irreversible hepatic disease Irreversible renal disease Irreversible neurological disease Medical nonadherence Severe psychosocial limitations Relative Age >80 y for destination therapy Obesity or malnutrition Musculoskeletal disease that impairs rehabilitation Active systemic infection or prolonged intubation Untreated malignancy Severe PVD Active substance abuse Impaired cognitive function Unmanaged psychiatric disorder Lack of social support

Referencies: Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895e1032; Theresa A McDonagh, Marco Metraet al. ESC Scientific Document Group , 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726



HF along Age

Elderly :

Vecteezy

- more than 10% in those aged 70 years or over have HF
- HFpEF patients are older

- <u>some of the comorbidities of HF are more common</u> in the elderly: arrhythmias and conduction disturbances (AF, pauses and atrioventricular block), stroke, frailty, sarcopenia, iron deficiency and anaemia, kidney dysfunction, arthritis, depression, ... They can:

... <u>limit the use of certain medications or compliance</u> with non-pharmacological measures

... promote the adoption of incorrect actions (eg. self-administeredNSAIDs)

Referencies: Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895e1032; Theresa A McDonagh, Marco Metra, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure are port of the American College of Safety (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726,



HF along Age

Elderly :




Older adults, especially those aged 75 years and with multiple disabilities, are underrepresented in most cardiovascular clinical trials, resulting in knowledge gaps related to cardiovascular care for this population

There is great heterogeneity and biological diversity in this population, which are independent of age





Biological age





Biological - Aging

Although the passage of time allows for greater exposure to known causes of HF (eg, coronary artery disease), it appears with age even in the absence of overt myocardial injury,...




... Biological Aging is the gradual deterioration of functional characteristics in living organism

(this the decline in intracellular quality control systems, across all organ systems does not "age" at the same rate)


... the aging cardiovascular system mirrors many of the phenotypes in HF

Referencies: Goyal P, Maurer MS, Roh J. Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series. JACC Heart Fail. 2024 May;12(5):795-809; Lazzeroni D, Villatore A, Souryal G, Pili G, Peretto G. The Aging Heart: A Molecular and Clinical Challenge. Int J Mol Sci. 2022 Dec 16;23(24):16033.

7th Advances in Heart Failure 2024



Referencies: Goyal P, Maurer MS, Roh J. Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series. JACC Heart Fail. 2024 May;12(5):795-809.



Lopez-Otin et al published the first reports on the **"hallmarks of aging,"** where they described the **fundamental biological processes** that dictate organismal **aging**

...all of them are <u>connected with complex interactions and interdependence</u> and all <u>contribute to HF pathophysiology</u>:

- 1. impaired proteostasis and autophgy (Amyloidosis, Sarcopenia)
- 2. mitochondria dysfunction: oxidative stress, metabolic reprogramming (Dementia, Frailty, Sarcopenia)
- 3. deregulated nutrient sensing (Cognitive impairment)
- 4. inflammation (Cachexia)
- 5. altered intercellular communication
- 6. telomere shortening
- 7. epigenetic alterations
- 8. cellular senescence
- 9. dysbiosis
- 10. stem cell exhaustion
- 11. Genomic instability
- 12. ...


and also dependent of lifestyle and environment factors





Biological - Aging

Several geriatric conditions, including malnutrition and cachexia, sarcopenia, frailty, and cognitive impairment, coexist with HF in part because of shared mechanisms of dysregulated biological aging







Biological - Aging

Geriatric conditions complicate management in HF given their well-known associations with adverse outcomes, including impaired quality of life, hospitalization, and reduced life expectancy even after adjustment for chronologic age.

Frailty and sarcopenia are particularly important







Biological age in HF





HF can accelerate Cardiac aging:

Heart failure promotes accelerated cardiac aging through several interconnected mechanisms:

- 1. Increased Oxidative Stress: HF leads to an overproduction of reactive oxygen species
- 2. Inflammation: chronic inflammation is a hallmark of heart failure leading to fibrosis and reduced heart function,
- 3. -Mitochondrial Dysfunction: energy deficits and increased oxidative stress
- 4. Telomere Shortening: a marker of cellular aging and can lead to cell death or dysfunction.
- 5. Cellular Senescence: cells stop dividing and release inflammatory factors
- 6. Impaired Autophagy: accumulation of damaged proteins and organelles, which accelerates aging



These mechanisms lead to:

- 1. Structural Changes: thickening, stiffening of the heart walls, which are also common in the natural aging process
- 2. Impaired Function: includes reduced cardiac reserve and impaired diastolic function.
- 3. Increased risk of arrhythmias: which can further damage the heart.





Fig. 3 Schematic presentation of the hemodynamic responses on the Guyton diagram for each subgroup during acute preload-increasing maneuver. The difference in hemodynamic responses to the increased preload according to age groupss and HFpEF are schematically presented in the Guyton diagram. *LPP* leg-positive pressure, *LV* left ventricular, *HFpEF* heart failure with preserved ejection fraction

These changes can lead to a decline in overall heart health and function... These are the structural and hemodynamic are the hallmarks of HFpEF: ... concentric hypertrophy, ... diastolic abnormalities, ...delayed relaxation, ... myocardial stiffening ... impairment of filling dynamics.

Referencies: Shono, A., Matsumoto, K., Yamada, N. et al. "Accelerated aging" of the heart as heart failure with preserved ejection fraction—analysis using leg-positive pressure stress echocardiography. Int J Cardiovasc Imaging **37**, 2473–2482 (2021).; Li H, Hastings MH, Rhee J et al, Targeting Age-Related Pathways in Heart Failure. Circ Res. 2020 Feb 14;126(4):533-551.; Lazzeroni D, Villatore A, Souryal G, et al, The Aging Heart: A Molecular and Clinical Challenge. Int J Mol Sci. 2022 Dec 16;23(24)








How can we be more personalized in care and have an early approach to HF in terms of age?









AGE and AGING



How can we be more personalized in care and have an early approach to HF in terms of age?

Table 10 Risk factors for the development of heart failure and potential corrective actions

Risk factors for heart failure	Preventive strategies
Sedentary habit	Regular physical activity
Cigarette smoking	Cigarette smoking cessation
Obesity	Physical activity and healthy diet
Excessive alcohol intake ²⁸⁶	General population: no/light alcohol intake is beneficial Patients with alcohol-induced CMP should abstain from alcohol
Influenza	Influenza vaccination
Microbes (e.g. Trypanosoma cruzi, Streptococci)	Early diagnosis, specific antimicrobial therapy for either prevention and/or treatment
Cardiotoxic drugs (e.g., anthracyclines)	Cardiac function and side effect moni- toring, dose adaptation, change of chemotherapy
Chest radiation	Cardiac function and side effect moni- toring, dose adaptation
Hypertension	Lifestyle changes, antihypertensive therapy
Dyslipidaemia	Healthy diet, statins
Diabetes mellitus	Physical activity and healthy diet, SGLT2 inhibitors
CAD	Lifestyle changes, statin therapy

CAD = coronary artery disease; CMP = cardiomyopathy; SGLT2 = sodium-glu-


Firstly – prevention:

... promote healthy life style habits: diet, regular exercise, healthy weight management, limit Alcohol and quit Smoking:

... **treat** adequately the most important **risk factors for the onset of HF**, such as diabetes, hypertension and obesity, excessive alcohol intake, coronary heart disease, ...










How can we be more personalized in care and have an early approach to HF in terms of age?



Second – high suspicion and early diagnosis:

... <u>think about</u> at-risk populations, particularly individuals over 50, but also children where diagnosis can sometimes be challenging ("the primary presenting complaints are often respiratory and/or gastrointestinal symptoms that can mimic more common pediatric illnesses, leading to incorrect and/or late diagnoses...") ...

... <u>identify early</u> individuals with subclinical or symptomatic cardiac pathology that could develop into heart failure;

Primary Care plays a fundamental role in the **early referral** of patients with strong diagnostic suspicion to **specialized HF Units/Consultations** so that the most improved etiological study can be carried out quickly:

... in Portugal, access to NTproBNP and echocardiography determine the initial approach

Referencies: Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335.; Theresa A McDonagh, Marco Metraet et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726



How can we be more personalized in care and have an early approach to HF in terms of age?

After diagnosis treat well to slow progression and anticipate exacerbations:

... <u>early institution and optimization of guideline-recommended therapy</u> (this is a challenge for children, given the rarity of heart failure in pediatrics and the heterogeneity of this population, leading to a lack of clinical trials in this population and also in the Elderly)

AHA/ACC/HFSA CLINICAL PRACTICE GUIDELINI

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Referencies: Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335.; Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-e1032; Theresa A McDonagh, Marco Metraet et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Sournal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726.



How can we be more personalized in care and have an early approach to HF in terms of age?

After diagnosis treat well to slow progression and anticipate exacerbations:

... <u>Team Work</u> - Primary Health Care vs Hospital HF Units, with patients moving between the two types of care according to their need and complexity is the ideal scenario:

- in the <u>stabilization</u> phase of the Syndrome, the role of Primary Health Care is vital to reinforce non-pharmacological **measures**, namely vaccination, weight loss, strengthening the importance of exercise, supervine compliance with therapy and optimization according to the guidelines; treating co-morbidities, give psychosocial support, ...

- facilitate the access to care in decompensation
- pay attention to <u>self-care</u> ...



Referencies: Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335.; Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-e1032; Theresa A McDonagh, Marco Metraet et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726.



How can we be more personalized in care and have an early approach to HF in terms of age?

Self-care:

- Many health and social factors are associated with poor HF self-care:

- ... Depression
- ... Frailty
- ... Social isolation.
- ... poor Social support
- ... inadequate/marginal Health literacy
- ... Cognitive impairment
- ... Homelessness or housing insecurity

... These are more common in the elderly

Referencies: Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895e1032; Theresa A McDonagh, Marco Metraet et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726.



How can we be more personalized in care and have an early approach to HF in terms of age?

Some age groups have particularities:

... Children - there is a lack of randomized clinical trials and international guidelines and optimal therapeutic

... Young adults - pregnancy, job, hobbies (travel, sports,...) family/small children

... Elderly

...



Referencies: Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):323-335.; Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-e1032; Theresa A McDonagh, Marco Metraet et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, *European Heart Journal*, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726.; https://www.heartfailurematters.org/



Geriatric Condition	Strategies for Enhanced Care Provision	Interventions Requiring Additional Study
Malnutrition	 Referral to dietitian/nutritionist Consideration of nutritional supplements Dietary recommendations (eg, increasing caloric intake and/or liberalizing dietary restrictions) Assessment of external factors that may be contributing to malnutrition (eg, financial means, taste, dental issues, social support) 	 Dietary modifications Nutritional/caloric supplementation Combining nutritional interventions with exercise Home-delivered meals Micronutrient supplementation
Cachexia	 Consideration of nutritional supplements Dietary recommendations (eg, increasing caloric intake and/or liberalizing dietary restrictions) Consideration for palliative care 	 Treatment of underlying causes such as her failure and other comorbid conditions Appetite stimulants Dietary modifications Nutritional/caloric supplementation
Sarcopenia	 Referral to physical and/or occupational therapy; provision of exercise prescription Exercise and resistance training Reassessment of prognosis and risk-benefit ratio of management options 	 Treatment of underlying causes such as her failure (eg, effect of GDMT) and other comort conditions Nutritional/caloric supplementation Resistance exercise training Testosterone replacement
Frailty	 Reassessment of prognosis and risk-benefit ratio of management options Emphasis on lifestyle recommendations such as exercise (home programs, cardiac rehabilitation programs, and strength-training) and nutrition 	Exercise
Cognitive impairment	 Engagement of social support (caregivers, family), services Referral for formal assessment and/or discussion with other clinicians (geriatrics and/or memory center) Reassessment of health goals/priorities Reassessment of prognosis and risk-benefit ratio of management options (especially related to medications) Consideration of novel agents to treat early Alzheimer dementia if present Consideration for palliative care 	 Treatment of underlying causes such as he failure and other comorbid conditions Exercise

Elderly

GDMT = guideline-directed medical therapy.



TABLE 4 Strategies and Potential Interventions for Managing Geriatric Conditions				
Geriatric Condition	Strategies for Enhanced Care Provision	Interventions Requiring Additional Study		
Malnutrition	 Referral to dietitian/nutritionist Consideration of nutritional supplements Dietary recommendations (eg, increasing caloric intake and/or liberalizing dietary restrictions) Assessment of external factors that may be contributing to malnutrition (eg, financial means, taste, dental issues, social support) 	 Dietary modifications Nutritional/caloric supplementation Combining nutritional interventions with exercise Home-delivered meals Micronutrient supplementation 		

Adopting a patient-centered-approach, which considers individual comorbidities, life expectancy, cognitive function, frailty, and patient preferences, is critical for establishing the optimal management strategy

	ratio of management options	Resistance exercise training Testosterone replacement
Frailty	 Reassessment of prognosis and risk-benefit ratio of management options Emphasis on lifestyle recommendations such as exercise (home programs, cardiac rehabilitation programs, and strength-training) and nutrition 	Exercise
Cognitive impairment	 Engagement of social support (caregivers, family), services Referral for formal assessment and/or discussion with other clinicians (geriatrics and/or memory center) Reassessment of health goals/priorities Reassessment of prognosis and risk-benefit ratio of management options (especially related to medications) Consideration of novel agents to treat early Alzheimer dementia if present Consideration for palliative care 	 Treatment of underlying causes such as heart failure and other comorbid conditions Exercise
GDMT = guideline-directed medical therapy.		

Referencies Goyal P, Maurer MS, Roh J. Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series. JACC Heart Fail. 2024 May;12(5):795-809av; Lazzeroni D, Villatore A, Souryal G, Pili G, Peretto G. The Aging Heart: A Molecular and Clinical Challenge. Int J Mol Sci. 2022 Dec 16;23(24):16033




How can we be more personalized in care and have an early approach to HF in terms of age?

In the Biological age:

Pre-clinical and clinical research

temonstrates that dietary restriction with adequate intake of specific nutrients, as well as regular exercise, stress management, and smoking cessation, are effective ways to prevent or delay the accumulation of molecular damage that results in tissue degeneration and rediometabolic dysfunction



Referencies Goyal P, Maurer MS, Roh J. Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series. JACC Heart Fail. 2024 May;12(5):795-809av; Fang Z, Raza U, et al. Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues. ESC Heart Fail. 2024 Jul 22; Lazzeroni D, Villatore A, Souryal G, Pili G, Peretto G. The Aging Heart: A Molecular and Clinical Challenge. Int J Mol Sci. 2022 Dec 16;23(24):16033



How can we be more personalized in care and have an early approach to HF in terms of age?

- Exercise:

... Physical activity regular and moderate promotes beneficial adaptations, affecting all hallmarks of aging and enhancing resiliency in essentially every organ system not only attenuates or reverses many of the cardiac phenotypes associated with aging, but it also improves the cellular mechanism associated to cellular decline like inflammation, mitochondrial function, proteostasis, metabolism, epigenetic alterations, telomerase activity, and even had regenerative potential of the heart

- Amiloidosis Therapeutics
- omega-3 and omega-6 polyunsaturated FAs (PUFAs), Coenzyme Q10,
- metformin
- canakinumab,
- anakinra, colchicine, methotrexate, infliximab
- pirfinidona
- empaglifozin
- ...





Take-Home Messages

Chronological age is immutable but is accompanied by problems, sometimes characteristic of each stage of life, which can be intervened on ...

Biological age is susceptible to interventions designed to slow the process of cellular and tissue degradation... but there is still a long way to go...

molecular damage that results in ussue aco

With the growing impact of aging, it is essential to reassess CV research, including the increased use of real-world studies to measure long-term effects. Clinical decision-making should integrate molecular and genetic indicators, pointing to personalized therapy. Remarkably, the identification of new molecular targets, as well as improved clinical characterization of older patients, may enhance knowledge and therapy f the aging heart.



Review Open access Published: 24 April 2023

A state-of-the-art review on the MicroRNAs roles in hematopoietic stem cell aging and longevity

Geovanny Genaro Reivan Ortiz, Yasaman Mohammadi, Ahmad Nazari, Mehrnaz Ataeinaeini, Parisa Kazen Saman Yasamineh 🖾, Bashar Zuhair Talib Al-Nageeb, Haider Kamil Zaidan & Omid Gholizadeh 🖾

Cell Communication and Signaling **21**, Article number: 85 (2023) Cite this article

Ageing Research Reviews Volume 9, Supplement, November 2010, Pages S59-S66

microRNA and aging: A novel modulator in regulating the aging network

Li-Hsin Chen ^{a c 1}, Guang-Yuh Chiou ^{a d 1}, Yi-Wei Chen ^{a d 1}, Hsin-Yang Li ^{b d}, Shih-Hwa Chiou a c d 🖉 🖾

Hum Genet. 2020 March ; 139(3): 291-308. doi:10.1007/s00439-019-02046-0.

MicroRNAs as modulators of longevity and the aging process

Holly E Kinser¹, Zachary Pincus²

¹Department of Biomedical Engineering, Washington University in St. Louis

²Department of Developmental Biology and Department of Genetics, Washington University in St. Louis

Abstract

MicroRNAs (miRNAs) are short, non-coding RNAs that post-transcriptionally repress translation or induce mRNA degradation of target transcripts through sequence-specific binding. miRNAs target hundreds of transcripts to regulate diverse biological pathways and processes, including aging. Many microRNAs are differentially expressed during aging, generating interest in their use as aging biomarkers and roles as regulators of the aging process. In the invertebrates C. elegans and Drosophila, a number of miRNAs have been found to both positive and negatively modulate longevity through canonical aging pathways. Recent studies have also shown that miRNAs regulate age-associated processes and pathologies in a diverse array of mammalian tissues, including brain, heart, bone, and muscle. The review will present an overview of these studies, highlighting the role of individual miRNAs as biomarkers of aging and regulators of longevity and tissue-specific aging processes.



Review > J Int Med Res. 2024 Oct;52(10):3000605241279190. doi: 10.1177/03000605241279190.

Impact of microRNAs on cardiovascular diseases and aging

Md Sayed Ali Sheikh ¹, Umme Salma ²

Affiliations + expand PMID: 39370977 DOI: 10.1177/03000605241279190 Free article

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for both men and women among all ethnicities worldwide. Although significant improvements in the management of CVD occurred in the 20th century, non-invasive, universal, early diagnostic biomarkers and newer therapeutic drugs are needed for clinical treatment by physicians. MicroRNAs (miRNAs) are a class of endogenous, non-coding, single-stranded, small RNA molecules that are critically controlled by all human biological processes. Moreover, dysregulated miRNA expression is directly involved in various CVDs, including stable coronary artery disease and acute coronary syndrome. Several miRNAs that are enriched in the plasma of CVD patients have potential as clinical biomarkers, and overexpression or inhibition of specific miRNAs has novel therapeutic significance in the management of CVD. Aging is a multifactorial physiological process that gradually deteriorates tissue and organ function and is considered a non-modifiable major risk factor for CVDs. Recently, several studies established that various miRNAs essentially regulate aging and aging-related disease processes. This narrative review briefly discusses the recently updated molecular involvement of miRNAs in CVDs, their possible diagnostic, prognostic, and therapeutic value, and their relationship to the aging process.

Keywords: Cardiovascular disease; aging; diagnosis; microRNA; prognosis; therapeutic.



International Journal of Molecular Sciences

The Aging Heart: A Molecular and Clinical Challenge

Davide Lazzeroni ¹^(b), Andrea Villatore ^{2,3}^(b), Gaia Souryal ², Gianluca Pili ² and Giovanni Peretto ^{2,3,*}^(b)

MicroRNAs

microRNAs (miRNAs) are involved in the aging process and help to regulate many mechanisms underlying cardiac changes in the elderly [17]. Aging is specifically associated with an increased expression of miR-34a, which is caused by an upregulation of p53 signaling. Indeed, the miR-34 family induces apoptosis, which emphasizes the central role of miR-34a in the mechanisms underlying aging [18]. Moreover, in aged cells, a reduced amount of miR-146a is found. MiR-146a reduces oxidative stress by downregulating the expression of NOX4, which is the major catalytic subunit of NADPH oxidase [19]. Some miRNAs, including the senescence-associated miR-17-92 cluster, have been shown to inhibit apoptosis [20]. Finally, the expression of miR-17, which is reduced by hypoxia, causes a downregulation of Casp9 and apoptotic protease-activating factor 1 (Apaf-1) [21].

MicroRNAs inhibition

MiR-217 is a biomarker of vascular aging and cardiovascular risk, as it regulates an endothelial signaling hub and downregulates a network of eNOS, including VEGF, which results in diminished eNOS expression [184]. A recent study by De Yebénes et al. [184] found out that the inhibition of endogenous vascular miR-217 in apo $E^{-/-}$ mice improved vascular contractility and diminished atherosclerosis, highlighting the therapeutic potential of miR-217 inhibitors.

Circulation Research


REVIEW

Targeting Age-Related Pathways in Heart Failure Haobo Li, Margaret H. Hastings, James Rhee, Lena E. Trager, Jason D. Roh, Anthony Rosenzweig®

MicroRNAs (miRNAs) are endogenous small ncRNAs, approximately 22 nucleotides long that work as post-transcriptional regulators by binding to complementary sequences of messenger RNAs (mRNAs) to inhibit mRNA translation or to promote mRNA degradation.¹⁵⁴ A number of miRNAs have been found to

have pathophysiological roles in HF. In a screen for 380 miRNAs in cardiomyocytes, miRNA (miR)-22 was identified as an abundant and strong inhibitor of cardiac autophagy, whose expression level increased during aging in mice in vivo and in cardiomyocytes in vitro by a p53-dependent mechanism.¹⁵⁵ Pharmacological





Muito obrigada pela vossa atenção!